Skin Laxity Clinical Trial
Official title:
Clinical Evaluation of the Safety and Efficacy of Using Multi-Polar Radio Frequency and Pulsed Electromagnetic Field Therapy Technologies for the Treatment of the Mon Pubis, Vaginal Introitus and Labia Skin Laxity
NCT number | NCT02770287 |
Other study ID # | CS2815 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | March 26, 2016 |
Est. completion date | November 30, 2017 |
Verified date | April 2020 |
Source | Venus Concept |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The study will confirm that the Freeze Diamond polar applicator is safe for treating the Mons pubis and Labia, and will result in improvement in general skin appearance including an improvement in skin irregularities and skin laxity.
Status | Completed |
Enrollment | 11 |
Est. completion date | November 30, 2017 |
Est. primary completion date | November 30, 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 25 Years to 65 Years |
Eligibility |
Inclusion Criteria: 1. Healthy female between the ages of 25 and 65. 2. Able to read, understand and voluntarily provide written Informed Consent; 3. Able and willing to comply with the treatment/follow-up schedule and requirements; 4. Fitzpatrick skin type I-VI. 5. Sexual activity (vaginal intercourse once per month) in a monogamous relationship. 6. Women of child-bearing age are required to be using a reliable method of birth control at least 3 months prior to study enrollment, and have a negative Urine Pregnancy test at baseline. 7. Women requesting aesthetic benefit to the vaginal mons, introitus and labia. Exclusion Criteria: 1. Pregnant or intending to become pregnant during the course of study. A urine pregnancy test will be given to women of childbearing potential and performed during initial visit. 2. Having any active electrical implant anywhere in the body, such as a pacemaker or an internal defibrillator. 3. Having a permanent implant in the treated area. 4. Prior use of retinoids in treated area within 2 weeks of initial treatment or during the course of the study. 5. Use of oral Isotretinoin (Accutane®) within 6 months of initial treatment or during the course of the study. 6. Patient on systemic corticosteroid therapy 6 months prior to and throughout the course of the study. 7. Prior skin treatment with laser in treated area within 6 months of initial treatment or during the course of the study. 8. Prior use of collagen, fat injections and /or other methods of skin augmentation (enhancement with injected or implanted material) in treated area within 4-6 weeks of initial treatment or during the course of the study. Treatment may not be performed at all over permanent dermal implants. 9. Prior ablative resurfacing procedure in treated area with laser or other devices within 12 months of initial treatment or during the course of the study. 10. Any other surgery in treated area within 12 months of initial treatment or during the course of the study. 11. History of keloid formation or poor wound healing in a previously injured skin area. 12. History of epidermal or dermal disorders (particularly if involving collagen or microvascularity). 13. Open laceration or abrasion of any sort on the area to be treated. 14. Active sexually transmitted disease (e.g. genital Herpes Simplex, condylomata) or vaginosis; any tissue biopsy will be deferred or delayed to a later time point until the infection is resolved. 15. Chronic vulvar pain or vulvar dystrophy. 16. History of immunosuppression/immune deficiency disorders (including human immunodeficiency virus infection or acquired immune deficiency syndrome) or use of immunosuppressive medications. 17. Having any form of active cancer at the time of enrollment and during the course of the study. 18. Significant concurrent illness, such as uncontrolled diabetes i.e. any disease state that in the opinion of the Investigator would interfere with the treatment, or healing process. 19. Participation in a study of another device or drug within 1 month prior to study enrollment or during this study, and as per the Investigator's careful discretion, as long as not contradictory to any of the above criteria. 20. Tattoos in the treatment area. 21. Mentally incompetent, prisoner or evidence of active substance or alcohol abuse. 22. Having any stage 3-4 cystocele, rectocele, enterocele paravaginal defect or major pelvic organ prolapse beyond the hymenal ring. |
Country | Name | City | State |
---|---|---|---|
United States | Revive Wellness Center | Torrance | California |
Lead Sponsor | Collaborator |
---|---|
Venus Concept |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | General Skin Appearance of Mons Pubis and Labia | Improvement in general skin appearance at follow-up visit 3 as compared to baseline as assessed by independent blinded evaluator by photographic assessment, utilizing the Global Aesthetic Improvement Scale (GAIS) where 3 = very much improved, 2 = much improved, 1 = improved, 0 = no change, -1 = worse, -2 = much worse and -3 = very much worse where higher scores indicate a better outcome. | Baseline - Day 1, Follow-up visit - Day 85 | |
Secondary | Visual Analogue Scale (VAS) | The subject records their measure of discomfort and pain associated with all treatments of the labia as a vertical line drawn on a 100 mm horizontal line on which the discomfort and pain intensity is represented by a point between the extremes of "no pain at all" (a value of 0 mm) and "worst pain imaginable (a value of 100 mm). | Treatment 1 - Day 1, Treatment 2 - Day 29, Treatment 3 - Day 57 | |
Secondary | Visual Analog Scale (VAS) | The subject records their measure of discomfort and pain associated with all treatments of the mons pubis as a vertical line drawn on a 100 mm horizontal line on which the discomfort and pain intensity is represented by a point between the extremes of "no pain at all" (a value of 0 mm) and "worst pain imaginable (a value of 100 mm). | Treatment 1 - Day 1, Treatment 2 - Day 29, Treatment 3 - Day 57 | |
Secondary | Vaginal pH | Vaginal pH was obtained at each study visit. The pH is a numeric value from 0 to 14 expressing the acidity or alkalinity of the vaginal fluids where 7 is neutral, lower values are more acidic (value of 0) and higher values more alkaline (value of 14). A healthly vaginal pH has a value of 3.8 to 4.5. | Treatment 1 - Day 1, Treatment 2 - Day 29, Treatment 3 - Day 57, Follow-up visit - Day 85 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT06140628 -
A 28-day Clinical Study on Facial Skin Rejuvenation
|
N/A | |
Completed |
NCT01713985 -
Feasibility Study: Evaluation of Ulthera Versus Thermage for Treating the Face and Neck
|
N/A | |
Completed |
NCT01971736 -
Efficacy of Long Pulsed 1064nm Laser for Facial Skin Tightening
|
N/A | |
Completed |
NCT01708252 -
Feasibility Study: Treatment of Post-surgery and Surgery Naive Patients Who Failed to Respond to a Previous Ulthera Treatment
|
N/A | |
Completed |
NCT01708382 -
Feasibility Study: Lifting and Tightening of the Elbows
|
N/A | |
Completed |
NCT01713998 -
Treatment of the Face and Neck With Lower Ulthera System Energy Settings
|
N/A | |
Completed |
NCT04296201 -
Evaluation of the Immediate Effect and Safety of DMA™ Novel Muscle Stimulation Technology
|
N/A | |
Completed |
NCT06000839 -
A Safety and Effectiveness Study of CELLBOOSTER® Lift (Stabilized Booster Complex Using CHAC Technology)
|
N/A | |
Completed |
NCT06366503 -
Evaluating Procedure Pairing of a Post-Procedure Cream Versus a Comparator in Patients Treated With Fractional Ablative CO2 Laser for Facial Rejuvenation
|
N/A | |
Completed |
NCT05929625 -
Radiofrequency and Ultrasound for Improvement of Skin Laxity and Wrinkles: Efficacy and Safety Evaluation
|
N/A | |
Terminated |
NCT01713569 -
Feasibility Study: Histological Characterization After Treatment With the Ulthera® System
|
N/A | |
Completed |
NCT01519934 -
A Retrospective Study to Evaluate the Effectiveness of the Ulthera System
|
N/A | |
Completed |
NCT05605691 -
Post-Market Lower Eyelid Treatment With Renuvion in Greece
|
N/A | |
Completed |
NCT04477187 -
Clinical Assessment of Skin Tightening and Contour Change of Submental Tissue Using Bipolar Radiofrequency Microneedling
|
N/A | |
Completed |
NCT05590364 -
Aesthetic Performance and Tolerance of an Injective Intradermal Treatment for the Skin Roughness and Laxity of Back of the Hands
|
N/A | |
Active, not recruiting |
NCT06243744 -
Histological Evaluation of Human Skin Bx to Assess the Effects of APR Tx as an Adjunct Procedure in Facelift Surgery
|
N/A | |
Completed |
NCT04146584 -
Safety and Efficacy of SofWave Treatment to Lift Lax Tissue in the Submental and Neck Zones and to Lift the Eyebrow
|
Phase 2 | |
Recruiting |
NCT05750901 -
Evaluation of Fractional Ablative Laser Treatment for Skin Conditions
|
N/A | |
Completed |
NCT04721600 -
Evaluation of the Evoke Radiofrequency Device for Improvement of Skin Appearance
|
N/A | |
Recruiting |
NCT06157567 -
Clinical Feasibility Study to Evaluate the Safety and Performance of the Profound Matrix System
|
N/A |